| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10961947 | Tuberculosis | 2015 | 8 Pages |
Abstract
An erroneous treatment strategy is unlikely to drive resistance development. Increasing patients' compliance, addressing issues of social support, rapid detection of drug resistance and improving infection control is crucial for prevention of further spread of X/MDRTB and achieving higher cure rates.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Olga Ignatyeva, Yanina Balabanova, Vladyslav Nikolayevskyy, Ekaterina Koshkarova, Birute Radiulyte, Edita Davidaviciene, Vija Riekstina, Kadri Jaama, Manfred Danilovits, Cristina M. Popa, Francis A. Drobniewski,